Medical Marijuana Inc is pleased to announce that studies have shown Cannabidiol (CBD) as a possible prevention and treatment for Alzheimer’s disease. Medical Marijuana Inc. through CannaBANK has a patent pending on an extraction method from Cannabis Sativa (Marijuana) and its industrialized non psychoactive counterpart Hemp, allowing Cannabidiol (CBD) to be isolated in its pure form.
According to the Alzheimer’s Association ( www.alz.org ), Alzheimer’s is said to cost $182 billion annually and is the 6th leading cause of death in the United States. This affects some 14.9 million family members and friends of Alzheimer’s patients, these family and friends provide an estimated 17 billion hours annually of unpaid care. With the recent increase of Cannabis (Marijuana) research over the past decade, research has shown that Cannabidiol (CBD) has a neuroprotective, anti-inflammatory, anti-oxidative and anti-apoptotic affect, which is associated with oxidative stress commonly known to be a cause of Alzheimer’s disease.
Medical Marijuana Inc. is planning on expanding its Cannabidiol sales through licensing agreements with companies already involved in the heavily marketed nutraceutical and pharmaceutical markets.
Resources and Abstracts: United States National Library of Medicine (PubMed)
ABOUT MEDICAL MARIJUANA INC
Our mission is to be the world’s premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate, invest in and purchase value-added sustainable companies, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, pay homage to the visionaries and activists of the past and present, and provide the platform from which the industry can emerge into a global sustainable economy for all. Medical Marijuana Inc recognizes the vast and unequaled opportunities that exist in the rapidly expanding hemp and medical marijuana industries. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion, thus opening the door for safe and lucrative investment opportunities.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana Inc to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA), products and statements are not intended to diagnose, treat, cure, or prevent any disease.
SOURCE: Medical Marijuana Inc.